URI:
   DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 2002--------------------------------------------------
       Zinbryta (daclizumab) pulled from market due to safety concerns
       By: agate Date: March 2, 2018, 3:46 pm
       ---------------------------------------------------------
       Zinbryta is being taken off the market, according to MedPage
       Today (March 2, 2018):
  HTML https://www.medpagetoday.com/neurology/multiplesclerosis/71501?xid=NL_breakingnews_2018-03-02&eun=g378374d0r
       #Post#: 2016--------------------------------------------------
       (Lancet editorial) End of the road for daclizumab in MS
       By: agate Date: March 16, 2018, 4:36 pm
       ---------------------------------------------------------
       [font=Verdana]An editorial in The Lancet (March 17, 2018) sums
       up the situation with Zinbryta (daclizumab), which has been
       taken off the market due to safety concerns:[/font]
  HTML http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30565-8/fulltext?{$trackingTag}
       #Post#: 2019--------------------------------------------------
       FDA announcement about Zinbryta
       By: agate Date: March 20, 2018, 8:28 pm
       ---------------------------------------------------------
       The FDA notification about Zinbryta, which will be available
       until April 30:
  HTML https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm
       #Post#: 2092--------------------------------------------------
       European EMA confirms severe risks associated w/MS drug Zinbryta
       By: agate Date: May 23, 2018, 6:27 pm
       ---------------------------------------------------------
       More on this in Multiple Sclerosis News Today, May 23,
       2018--"European EMA Confirms Severe Risks Associated with MS
       Drug Zinbryta":
  HTML https://multiplesclerosisnewstoday.com/2018/05/23/ema-confirms-serious-risks-ms-medicine-zinbryta/?utm_source=Multiple+Sclerosis&utm_campaign=4334878b10-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-4334878b10-71286581
       #Post#: 2151--------------------------------------------------
       (Abst.) DRESS syndrome and daclizumab failure--were dangerous si
       gns missed in clinical trials?
       By: agate Date: July 18, 2018, 3:19 pm
       ---------------------------------------------------------
       More on the failure of Zinbryta--from PubMed, July 18,
       2018--DRESS syndrome and daclizumab failure--Were potentially
       dangerous signs missed in clinical trials?":
  HTML https://www.ncbi.nlm.nih.gov/pubmed/30013311
       DRESS syndrome = drug reaction with eosinophilia and systemic
       symptoms
       This case history (see link below) goes into more detail about
       DRESS syndrome--appearing in Neurology (September 1, 2018) under
       the title "Drug reaction with eosinophilia after daclizumab
       therapy in MS":
  HTML http://nn.neurology.org/content/5/5/e479
       #Post#: 2172--------------------------------------------------
       (Abst.) Case of immune-mediated encephalitis related to daclizum
       ab therapy
       By: agate Date: August 4, 2018, 11:00 am
       ---------------------------------------------------------
       From PubMed (August 4, 2018). The same issue of Multiple
       Sclerosis Journal, which is where the article appears, includes
       an article entitled "Immune-mediated encephalitis with
       daclizumab: The final nail."  The article below is entitled "A
       case of immune-mediated encephalitis related to daclizumab
       therapy."
  HTML https://www.ncbi.nlm.nih.gov/pubmed/30073905
       #Post#: 2354--------------------------------------------------
       (Abst.) Severe meningo-encephalitis after daclizumab therapy for
        MS
       By: agate Date: January 22, 2019, 1:48 am
       ---------------------------------------------------------
       The study concerns 7 patients, 2 of whom died. From Multiple
       Sclerosis Journal (January 19, 2019)--"Severe
       meningo-/encephalitis after daclizumab therapy for multiple
       sclerosis."
  HTML https://journals.sagepub.com/doi/abs/10.1177/1352458518819098
       #Post#: 2664--------------------------------------------------
       Daclizumab-induced encephalitis in MS
       By: agate Date: September 26, 2019, 12:39 am
       ---------------------------------------------------------
       Editorial in Multiple Sclerosis Journal (September 24,
       2019)--"Daclizumab-induced encephalitis in multiple sclerosis":
  HTML https://journals.sagepub.com/doi/full/10.1177/1352458519845079
       *****************************************************